ADHD in the News 2020-11-12

People with mental disorder diagnosis at increased risk for COVID-19 infection

Individuals who were recently diagnosed with a mental disorder were at increased risk for COVID-19 infection, especially African Americans and women, according to study results published in World Psychiatry.

Expert provides effective strategies for treating adult ADHD

Several psychopharmacological and psychotherapeutic interventions can help treat adult ADHD, according to a presenter at the NEI Max virtual conference. “ADHD is predicated on childhood and adolescent presentation of ADHD symptoms, but there's also the term called late-onset ADHD,” David W. Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, said in a presentation at NEI Max.

ADHD in Bipolar Patients: Genetics, Diagnosis, and Treatment

A recent study found that children diagnosed with attention deficit/hyperactivity disorder (ADHD) had a 10-fold increase in the incidence of later development of bipolar disorder compared with matched children without ADHD.1 The comorbidity is common, has a more severe course than either diagnosis alone, and is associated with greater risk of suicide attempts.2

Maternal Use of Valproic Acid Linked to ASD, ADHD in Offspring

Maternal use of valproic acid, but not lamotrigine, is associated with an increased risk for autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) among children, according to a study published online Oct. 28 in Neurology.

Long-Acting Psychostimulants Improve Adolescent Drivers with ADHD

A team, led by Daniel J. Cox, University of Virginia Health Sciences Center, Department of Psychiatry and Neurobehavioral Sciences, investigated the non-inferiority of 2 long-acting psychostimulants on driving performance in young adults with ADHD...In the randomized, double-blind, cross-over procedure, each participant was dose-optimized on controlled-release methylphenidate PRC-063 (45, 70, or 100 mg/day) or lisdexamfetamine (30, 50, or 70 mg/day).

PRC-063 Helps Treat Adults with ADHD

A team, led by Ann C. Childress, Center for Psychiatry and Behavioral Medicine, assessed the clinical efficacy, time to onset and duration of efficacy, and safety of PRC-063 compared to placebo in adult ADHD patients...PRC-063 is an extended-release formulation designed specifically to provide sustained delivery for patients with ADHD who require symptom control throughout the day.

David W. Goodman, MD: New Treatments Coming for ADHD

There are a number of new treatments and therapies coming on board for attention deficit/hyperactivity disorder (ADHD). During the annual Neuroscience Education Institute Max! Virtual meeting, David Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, will present 5 different times about ADHD and some new insights into the disorder.

Andrew J. Cutler, MD: Screening Techniques for ADHD

Screening for attention deficit/hyperactivity disorder (ADHD) has not changed much over the years...While there are tools to help the psychiatry screen patients for the disorder, a high degree of suspicion remains the most important aspect of screening for ADHD.

Andrew J. Cutler, MD: Neuroimaging for ADHD

In an interview with HCPLive®, Andrew J. Cutler, MD, Clinical Professor of Psychiatry at SUNY Upstate Medical University, explained the disappointment in the inability to leverage some of the emerging technologies being utilized in other spaces to detect ADHD early in patients.

DEA Expanding Surveillance of Prescription Drug Data

The U.S. Drug Enforcement Administration is making plans for a major expansion of its monitoring of prescriptions for opioids and other controlled substances, with the goal of identifying virtually every prescriber, pharmacy and patient in the country that shows signs of drug diversion or abusing their medication.